Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


18.03.2019

1 Am J Hematol
1 Ann Hematol
6 Blood
1 Cancer
1 Cancer Res
3 Genes Chromosomes Cancer
1 Int J Hematol
1 J Pediatr Hematol Oncol
1 Leuk Lymphoma
4 Leuk Res
13 Leukemia
1 Oncogene
1 Oncol Rep
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. BAIR SM, Porter DL
    Accelerating CAR therapy in CLL: The development and challenges of CAR T cell therapy for chronic lymphocytic leukemia.
    Am J Hematol. 2019 Mar 12. doi: 10.1002/ajh.25457.
    PubMed     Text format     Abstract available


    Ann Hematol

  2. GAJENDRA S, Yadav AK, Chugh B, Sood N, et al
    Clinicohematologic and cytogenetic profile in a rare case of pure erythroid leukemia.
    Ann Hematol. 2019 Mar 11. pii: 10.1007/s00277-019-03660.
    PubMed     Text format    


    Blood

  3. LIU H
    Mixed-phenotype acute leukemia with t(4;11)(q21;q23) KMT2A-AFF1-rearranged.
    Blood. 2019;133:1265.
    PubMed     Text format    

  4. FRANCISCHETTI IMB, Calvo KR
    Hairy cell leukemia coexistent with chronic lymphocytic leukemia.
    Blood. 2019;133:1264.
    PubMed     Text format    

  5. FLINN IW, Gribben JG, Dyer MJS, Wierda W, et al
    Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
    Blood. 2019 Mar 12. pii: blood-2019-01-896290. doi: 10.1182/blood-2019-01-896290
    PubMed     Text format     Abstract available

  6. PAIETTA E
    Consensus on MRD in AML?
    Blood. 2018;131:1265-1266.
    PubMed     Text format    

  7. WYNNE J, Stock W
    "Dar"-ing to target CD38 in T-ALL.
    Blood. 2018;131:948-949.
    PubMed     Text format    

  8. THOMPSON PA
    MRD negativity as a surrogate for PFS in CLL?
    Blood. 2018;131:943-944.
    PubMed     Text format    


    Cancer

  9. VANDSEMB EN, Kim TK, Zeidan AM
    Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?
    Cancer. 2019 Mar 12. doi: 10.1002/cncr.32042.
    PubMed     Text format    


    Cancer Res

  10. DIAZ-FLORES E, Comeaux EQ, Kim KL, Melnik EM, et al
    BCL-2 is a Therapeutic Target For Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.
    Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-0236.
    PubMed     Text format     Abstract available


    Genes Chromosomes Cancer

  11. IKEDA J, Shiba N, Tsujimoto SI, Yoshida M, et al
    Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia.
    Genes Chromosomes Cancer. 2019 Mar 14. doi: 10.1002/gcc.22751.
    PubMed     Text format     Abstract available

  12. TIONG IS, Wei AH
    New drugs creating new challenges in acute myeloid leukemia.
    Genes Chromosomes Cancer. 2019 Mar 12. doi: 10.1002/gcc.22750.
    PubMed     Text format     Abstract available

  13. MADZIO J, Pastorczak A, Sedek L, Braun M, et al
    GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
    Genes Chromosomes Cancer. 2019 Mar 11. doi: 10.1002/gcc.22748.
    PubMed     Text format     Abstract available


    Int J Hematol

  14. FUJINO H, Ishida H, Iguchi A, Onuma M, et al
    High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS).
    Int J Hematol. 2019 Mar 12. pii: 10.1007/s12185-019-02627.
    PubMed     Text format     Abstract available


    J Pediatr Hematol Oncol

  15. SCHLOSSER MP, Bucking S, Lemyre B, Grynspan D, et al
    Prenatally Diagnosed Infant AML.
    J Pediatr Hematol Oncol. 2018;40:238-239.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  16. BUCKLEY SA, Mark NM, Othus M, Estey EH, et al
    Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms.
    Leuk Lymphoma. 2019 Mar 11:1-4. doi: 10.1080/10428194.2019.1581933.
    PubMed     Text format    


    Leuk Res

  17. WANG YH, Imai Y, Shiseki M, Tanaka J, et al
    Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
    Leuk Res. 2018;67:99-108.
    PubMed     Text format     Abstract available

  18. WANG ES, O'Dwyer K
    High dose daunorubicin: New standard of care for FLT3 ITD mutant AML.
    Leuk Res. 2018;69:87-88.
    PubMed     Text format    

  19. TURCSANYI P, Kriegova E, Kudelka M, Radvansky M, et al
    Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
    Leuk Res. 2019;79:60-68.
    PubMed     Text format     Abstract available

  20. ANNIBALI O, Crescenzi A, Tomarchio V, Pagano A, et al
    PD-1 /PD-L1 checkpoint in hematological malignancies.
    Leuk Res. 2018;67:45-55.
    PubMed     Text format     Abstract available


    Leukemia

  21. PFEIFER H, Cazzaniga G, van der Velden VHJ, Cayuela JM, et al
    Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
    Leukemia. 2019 Mar 11. pii: 10.1038/s41375-019-0413.
    PubMed     Text format     Abstract available

  22. RADPOUR R, Riether C, Simillion C, Hopner S, et al
    CD8(+) T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia.
    Leukemia. 2019 Mar 15. pii: 10.1038/s41375-019-0441.
    PubMed     Text format     Abstract available

  23. JANSSEN L, Frambach SJCM, Allard NAE, Hopman MTE, et al
    Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0443.
    PubMed     Text format    

  24. TEFFERI A, Mudireddy M, Mannelli F, Begna KH, et al
    Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts.
    Leukemia. 2018;32:1200-1210.
    PubMed     Text format     Abstract available

  25. WONG ACH, Rasko JEJ, Wong JJ
    We skip to work: alternative splicing in normal and malignant myelopoiesis.
    Leukemia. 2018;32:1081-1093.
    PubMed     Text format     Abstract available

  26. ZAMPINI M, Tregnago C, Bisio V, Simula L, et al
    Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.
    Leukemia. 2018;32:1124-1134.
    PubMed     Text format     Abstract available

  27. JETANI H, Garcia-Cadenas I, Nerreter T, Thomas S, et al
    CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib.
    Leukemia. 2018;32:1168-1179.
    PubMed     Text format     Abstract available

  28. BILL M, Papaioannou D, Karunasiri M, Kohlschmidt J, et al
    Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells.
    Leukemia. 2019 Mar 11. pii: 10.1038/s41375-019-0429.
    PubMed     Text format     Abstract available

  29. AKKAPEDDI P, Fragoso R, Hixon JA, Ramalho AS, et al
    A fully human anti-IL-7Ralpha antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.
    Leukemia. 2019 Mar 8. pii: 10.1038/s41375-019-0434.
    PubMed     Text format     Abstract available

  30. MEGGENDORFER M, Cappelli LV, Walter W, Haferlach C, et al
    IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies.
    Leukemia. 2018;32:1249-1253.
    PubMed     Text format    

  31. VENDRAMINI E, Bomben R, Pozzo F, Benedetti D, et al
    KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.
    Leukemia. 2019 Mar 14. pii: 10.1038/s41375-019-0444.
    PubMed     Text format    

  32. DAVIDSSON J, Puschmann A, Tedgard U, Bryder D, et al
    SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies.
    Leukemia. 2018;32:1106-1115.
    PubMed     Text format     Abstract available

  33. ZHENG W, O'Hear CE, Alli R, Basham JH, et al
    PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
    Leukemia. 2018;32:1157-1167.
    PubMed     Text format     Abstract available


    Oncogene

  34. LIN J, Ma JC, Yang J, Yin JY, et al
    Arresting of miR-186 and releasing of H19 by DDX43 facilitate tumorigenesis and CML progression.
    Oncogene. 2018;37:2432-2443.
    PubMed     Text format     Abstract available


    Oncol Rep

  35. BASHANFER SAA, Saleem M, Heidenreich O, Moses EJ, et al
    Disruption of MAPK1 expression in the ERK signalling pathway and the RUNX1RUNX1T1 fusion gene attenuate the differentiation and proliferation and induces the growth arrest in t(8;21) leukaemia cells.
    Oncol Rep. 2019;41:2027-2040.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  36. LEUNG KK, Nguyen A, Shi T, Tang L, et al
    Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome.
    Proc Natl Acad Sci U S A. 2019;116:695-700.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: